Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
QuidelOrtho Shares Rise 9% On Better-than-expected Q1 Prel. Revenue
-
$300 Million In Silk Road Bitcoins On The Move After CPI Data
-
Will Bitcoin Price Crash To $10,000? Bloomberg Expert Reveals When
-
Bitcoin Shrimps and Crabs Accumulate BTC Aggressively Amid Heightened Institutional Interest
-
MicroStrategy Splurges $150 Million On Bitcoin, Repays $205 Million Silvergate Loan At 22% Discount